Understanding early decisions in ATMP research and development
From research to therapy – what you need to know early to develop cell and gene therapies.
On 30 September, a half-day training will be held at Medicon Village for researchers working in cell and gene therapy. This training is organised within the ATMP Path2Patient project.
The speakers focus on how early decisions in research can influence what is possible later in the development of new therapies. Topics also include funding pathways, how to protect research results, and how early scientific choices relate to future development, manufacturing, and clinical feasibility.
The training is open to researchers at all levels and does not require a defined development project. It also provides an overview of available support and resources within the ATMP field in the region.
Practical information
- Date: 30 September
- Location: Bistro Merge, Medicon Village, Lund
- Format: Half-day + lunch and mingle at Restaurant Inspira
- Registration and more info: Link to event page
Contact
Cecilia Jädert, Ph.D. | cecilia.jadert@innovation.lu.se
ATMP Path2Patient
This training is organised within ATMP Path2Patient, an EU co-funded initiative in southern Sweden, bringing together stakeholders to strengthen the ecosystem and provide tailored early support for the development and commercialization of cutting-edge research in Advanced Therapy Medicinal Products (ATMPs) – next-generation cell and gene therapies.